No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma

from Oncology Learning Network · host HMP Global

Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.

Episode metadata supplied by the publisher feed · Published Jun 9, 2020

Embed this episode

Attribution link and audio player

Ready to play

No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma

0:00 3:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 3 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on June 9, 2020.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!